<DOC>
	<DOCNO>NCT02686944</DOCNO>
	<brief_summary>The study prospective single arm , open label phase I study . Patients advance metastatic GIST tumor progression despite ongoing treatment second , third fourth line TKI treatment , least one measureable tumor lesion , eligible study . A maximum 12 patient include study . The patient continue TKI treatment 3 month follow visit . If tumor progression TKI withdrawn stable disease objective response patient continue TKI progress . The investigational product Intuvax inject tumor lesion two three treatment occasion ; day 1 , 14 day ( ±3 day ) first vaccination , 28 day ( ±3 day ) second vaccination ( patient 7-12 ) . Intuvax inject viable part tumor , use ultrasound-guided CT technique correct administration .</brief_summary>
	<brief_title>A Study Evaluate Safety Intuvax Administered Intra-tumorally Patients With Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>1 . Be inform nature study provide write informed consent . 2 . At least 18 year age . 3 . Diagnosis GIST ( accord modify NIH criterion , 2011 ) curative excision long option , i.e . confirm unresectable metastatic GIST , progress second , third fourth line tyrosine kinase inhibitor ( TKI ) treatment . 4 . Radiologically measurable tumor ( ) , i.e least 3 cm long unidimensional diameter measure CT 5 . Clinical and/or CT verify disease progression despite ongoing second , third fourth line treatment TKI 6 . Female postmenopausal one ( 1 ) year female childbearing potential use highly efficient method contraception ( i.e . method le 1 % failure rate [ e.g . sterilization , hormone implant , hormone injection , intrauterine device , vasectomized partner combine use condom and/or birth control pills ] ) study participation . Female childbearing potential must negative blood pregnancy test Screening , randomize vaccination negative blood urine pregnancy test within one ( 1 ) day dose Intuvax , Male agree use condom study participation male female partner use highly efficient method contraception describe partner 's study participation . 1 . Performance status &gt; ECOG 2 2 . Known major reaction/adverse event connection previously make vaccination ( e.g . asthma , anaphylaxia serious reaction ) 3 . Known major reaction/adverse event connection previous transfusion blood product 4 . Active autoimmune disease require treatment systemic immunosuppressive agent , e.g . inflammatory bowel disease , multiple sclerosis , sarcoidosis , psoriasis , autoimmune hemolytic anemia , rheumatoid arthritis , SLE , vasculitis , Sjögren 's syndrome , scleroderma , autoimmune hepatitis , rheumatological disease . 5 . Tested positive HIV 6 . Active virus disease ( HBV HCV ) . 7 . Ongoing infection require treatment parenteral antibiotic antiviral medication 8 . Corticosteroid treatment per o exceed 10mg/day within 7 day prior first injection Intuvax . Inhaled , intranasal local steroid accept . 9 . Inadequate laboratory parameter , i.e . : BLeukocyte count &lt; 3.0 x109/L BPlatelet count &lt; 75 x109/L BHemoglobin &lt; 100 g/L PProthrombincomplex ( PK ) &gt; 1.4 PAPT time outside normal limit 10 . Previous organ transplantation 11 . Pregnant lactate woman 12 . Life expectancy le 3 month . 13 . Investigational treatment ( within 28 day ) prior first injection Intuvax 14 . Known blood dyscrasia ( bleed complication ) 15 . Prior history invasive cancer within 5 year screen , except adequately treat situ carcinoma non melanoma skin cancer 16 . History alcohol substance abuse 17. patient available follow assessment 18 . Any reason , opinion investigator , contraindicate patient participates study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>GIST</keyword>
</DOC>